Immunovant to Host Graves’ Disease Program Update on September 9, 2024
Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program. The presentation will cover:
- New epidemiologic data on the potential addressable market
- Additional results from the Phase 2 study of batoclimab
- An overview of the IMVT-1402 development program in GD
Investors can register for the event through a provided link, and a live webcast will be available on Immunovant's website. A replay of the event and presentation will be accessible immediately after the webcast concludes.
Immunovant (Nasdaq: IMVT) ha annunciato un webcast per gli investitori previsto per il 9 settembre 2024, alle 8:00 ET per fornire aggiornamenti sul suo programma sulla Malattia di Graves (GD). La presentazione tratterà:
- Nuovi dati epidemiologici sul mercato potenzialmente affrontabile
- Ulteriori risultati dallo studio di Fase 2 di batoclimab
- Una panoramica del programma di sviluppo IMVT-1402 nella GD
Gli investitori possono registrarsi per l'evento tramite un link fornito, e un webcast dal vivo sarà disponibile sul sito web di Immunovant. Una registrazione dell'evento e della presentazione sarà accessibile immediatamente dopo la conclusione del webcast.
Immunovant (Nasdaq: IMVT) ha anunciado un webcast para inversores programado para el 9 de septiembre de 2024, a las 8:00 a.m. ET para proporcionar actualizaciones sobre su programa de Enfermedad de Graves (GD). La presentación cubrirá:
- Nuevos datos epidemiológicos sobre el mercado potencialmente accesible
- Resultados adicionales del estudio de Fase 2 de batoclimab
- Una visión general del programa de desarrollo IMVT-1402 en GD
Los inversores pueden registrarse para el evento a través de un enlace proporcionado, y un webcast en vivo estará disponible en el sitio web de Immunovant. Una repetición del evento y la presentación estará accesible inmediatamente después de que concluya el webcast.
Immunovant (Nasdaq: IMVT)는 2024년 9월 9일 오전 8시 ET에 그레이브스 병(GD) 프로그램에 대한 업데이트를 제공하기 위해 투자자 웹캐스트를 예정하고 있다고 발표했습니다. 발표 내용은 다음과 같습니다:
- 잠재적 시장에 대한 새로운 역학 데이터
- 바토클리맙의 2상 연구에서의 추가 결과
- GD에서의 IMVT-1402 개발 프로그램 개요
투자자들은 제공된 링크를 통해 행사에 등록할 수 있으며, Immunovant의 웹사이트에서 실시간 웹캐스트를 이용할 수 있습니다. 웹캐스트가 종료된 후 즉시 행사와 발표의 재생이 가능합니다.
Immunovant (Nasdaq: IMVT) a annoncé un webcast pour investisseurs programmé pour le 9 septembre 2024 à 8h00 ET afin de fournir des mises à jour sur son programme de Maladie de Graves (GD). La présentation portera sur :
- Nouvelles données épidémiologiques sur le marché potentiellement accessible
- Résultats supplémentaires de l'étude de Phase 2 sur le batoclimab
- Un aperçu du programme de développement IMVT-1402 dans la GD
Les investisseurs peuvent s'inscrire pour l'événement via un lien fourni, et un webcast en direct sera disponible sur le site web d'Immunovant. Un replay de l'événement et de la présentation sera accessible immédiatement après la fin du webcast.
Immunovant (Nasdaq: IMVT) hat eine Investor-Webcast für den 9. September 2024 um 8:00 Uhr ET angekündigt, um Updates zu seinem Morbus Basedow (GD)-Programm bereitzustellen. Die Präsentation umfasst:
- Neue epidemiologische Daten zum potenziell adressierbaren Markt
- Zusätzliche Ergebnisse aus der Phase-2-Studie zu Batoclimab
- Ein Überblick über das Entwicklungsprogramm IMVT-1402 in GD
Investoren können sich über einen bereitgestellten Link für die Veranstaltung anmelden, und ein Live-Webcast wird auf der Website von Immunovant verfügbar sein. Eine Wiederholung der Veranstaltung und der Präsentation wird sofort nach Abschluss des Webcasts zugänglich sein.
- None.
- None.
Investor webcast on Monday, September 9th at 8:00 a.m. ET
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.
The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Investor Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
Source: Immunovant Inc.
FAQ
When is Immunovant's investor webcast for the Graves' Disease program update?
What topics will be covered in Immunovant's Graves' Disease program update?
How can investors access Immunovant's Graves' Disease program update webcast?
What is Immunovant's stock symbol?
